Physician profile
Shelly Marie Seward
NPI 1053528299
$348,515.41
in general payments reported to CMS, 2019-2025
24 companies · $26K in 2025
The $26K reported for 2025 was more than what 95% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111K · 2020: $47K · 2021: $62K · 2022: $31K · 2023: $30K · 2024: $42K · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $72K · Consulting Fee: $18K · Travel and Lodging: $5,942 · Food and Beverage: $2,274 · Education: $64.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $71,632.00 |
| Consulting Fee | $18,133.00 |
| Travel and Lodging | $5,942.38 |
| Food and Beverage | $2,273.81 |
| Education | $64.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $192,669.25 | 2019-2025 | Lynparza |
| Glaxosmithkline, LLC. | $71,809.07 | 2020-2025 | Jemperli, Zejula |
| Abbvie INC. | $34,283.74 | 2024-2025 | |
| Tesaro, INC. | $18,752.55 | 2019 | |
| Immunogen, INC. | $18,023.03 | 2023-2024 | Elahere, Elahere |
| Merck Sharp & Dohme LLC | $11,228.97 | 2019-2024 | Keytruda, Lynparza |
| Daiichi Sankyo INC. | $969.59 | 2023-2024 | Enhertu |
| Seagen INC. | $189.46 | 2021-2023 | Tivdak |
| Eisai INC. | $159.74 | 2019-2024 | |
| Aspira Women'S Health INC | $120.35 | 2019 | |
| Gauss Surgical INC. | $99.87 | 2019 | |
| Clovis Oncology, INC. | $43.36 | 2019-2022 | |
| Ethicon US, LLC | $27.24 | 2022-2023 | Vistaseal, Harmonic, Mega Soft |
| Baxter Healthcare | $25.00 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.70 | 2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $21.77 | 2023 | Precisetumor |
| Kyowa Kirin, INC. | $19.85 | 2019 | |
| Pfizer INC. | $19.70 | 2024 | |
| Caris Mpi, INC. | $17.54 | 2025 | Mi Cancer Seek |
| Amgen INC. | $12.63 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shelly Seward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.